Video

Dexamethasone plug opens opportunity for treatment that will bring patients relief, help alleviate and mitigate the signs and symptoms associated with conjunctivitis from allergies

Author(s):

A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.

Now we have the opportunity — in a very controlled fashion by you the ophthalmologist, or the optometrist — to place a dexamethasone plug or insert into the canaliculus — or into the punctum — and will enjoy 30 days of sustained and tapering treatment with dexamethasone leeching onto the ocular surface with every blink.

This transcript has been lightly edited for clarity.

I'm Dr. Steve Silverstein with Silverstein Eye Centers in Kansas City, Missouri.

As most physicians are aware by now, Dextenza, or the dexamethasone punctal insert, has been approved and widely utilized for the treatment of postoperative pain and inflammation associated with intraocular surgery.

But now we have a second FDA indication for the treatment of allergic conjunctivitis.

For many years, doctors have shied away from the use of steroids in the cases of allergic conjunctivitis because primarily of their opportunity for abuse and overuse while patients want to achieve that level of comfort and clearing of their allergic conjunctivitis signs and symptoms. So we've been left with using non-steroidal anti-inflammatories, which have good utilization in patients with mild symptoms, but for the more moderate to severe cases of allergic conjunctivitis, the treatment has really been left short.

Now we have the opportunity — in a very controlled fashion by you the ophthalmologist, or the optometrist — to place a dexamethasone plug or insert into the canaliculus — or into the punctum — and will enjoy 30 days of sustained and tapering treatment with dexamethasone leeching onto the ocular surface with every blink.

It really has opened up an opportunity for appropriate treatment that will bring patients tremendous relief that will help alleviate and mitigate the signs and symptoms associated with conjunctivitis from allergies, both seasonal and perennial, and also do so in a safe manner without the potential for misconduct or misutilization of the product.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.